AstraZeneca announced positive Phase 3 lung cancer trial results and earned EU approval for its Enhe

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces positive h

Findings build on the established success of the global SAFFRON and China SACHI trials, extending th

Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-a

Oracle Named a Leader in the 2026 Gartner Magic Quadrant™ for Supply Chain Management Suites PR N

AstraZeneca reports mixed lung cancer trial data, highlighting successes for Tagrisso and Enhertu wh

First global Phase III trial to show significant progression-free and overall survival benefits in t

HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $0.09 per share. This is a 96.55 percen

Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and lowers

B of A Securities analyst Alec Stranahan maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and l

HUTCHMED reported positive Phase 2 data for fanregratinib in advanced ICC as China reviews the drug.

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile ——The

Companies granted approval by the China National Medical Products Administration ("NMPA") fo

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the New

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and low

HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM; HKEX:13) tod

HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $2.62 per share which beat the analyst

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced

HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a

NDA supported by results from a Phase II registration trial in China —— Second most common form of l

— First-in-human trial of candidate from the next-generation ATTC platform —— Simultaneous China and

— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with syner

First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent ta

new and updated data from several studies of compounds discovered by HUTCHMED will be presented at t

Morgan Stanley analyst Jack Lin downgrades HUTCHMED (China) (NASDAQ:HCM) from Equal-Weight to Und

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and rai

Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or de

— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significan

The China's National Medical Products Administration ("NMPA") has granted Breakthrough T

SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO®

Hutchmed forecasts 2025 oncology revenue of $350–$450 million after a strong 65% growth in 2024, dri

FINANCIAL GUIDANCEHUTCHMED provides full year 2025 guidance for Oncology/Immunology consolidated rev

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings a

U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are

U.S. stocks traded higher Wednesday, with the Dow Jones gaining around 100 points. Here are some bi

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in

Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares gained 188.8% to $4.13. The stoc

U.S. stocks traded lower, with the Nasdaq Composite falling around 70 points on Tuesday. Here are so

Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss

Gainers Liquid Media Group Ltd. (NASDAQ: YVR) jumped 88.1% to $0.2719.

U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some bi